News
Videos
Conferences
Events
Resources
Subscribe

|Videos|January 20, 2016

Pancreatic Cancer: Donald's Story

Episodes in this series

EP. 1 Treatment Options and Challenges for Patients With Pancreatic Cancer

EP. 1 Treatment Options and Challenges for Patients With Pancreatic Cancer

EP. 2 A Promising Future for Pancreatic Cancer

EP. 2 A Promising Future for Pancreatic Cancer

EP. 3 Pancreatic Cancer: David's Story to Remission

EP. 3 Pancreatic Cancer: David's Story to Remission

EP. 4 Pancreatic Cancer: Donald's Story

EP. 4 Pancreatic Cancer: Donald's Story

EP. 5 Locating Support Resources for Patients

EP. 5 Locating Support Resources for Patients

EP. 6 Treatment Considerations for Patients Researching Their Options

EP. 6 Treatment Considerations for Patients Researching Their Options

EP. 7 Moving Forward With Pancreatic Cancer

EP. 7 Moving Forward With Pancreatic Cancer

EP. 8 Receiving a Second Opinion

EP. 8 Receiving a Second Opinion

EP. 9 Maintenance Therapy: What to Expect

EP. 9 Maintenance Therapy: What to Expect

Newsletter

Stay up to date on cancer updates, research and education

Related Content

breast cancer

Ibrance Adds 15 Months of Progression-Free Survival in HR+, HER2+ Breast Cancer

January 30th 2026

Bonnie Annis

The Last Walk Down the Hall: Reflections Before Entering Cancer Survivorship

January 30th 2026

Dr. Brittany Dulmage explains how biotin can interfere with lab testing during cancer care: © The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

Biotin, Lab Interference and Safer Options for Cancer-Related Hair Loss

January 30th 2026

breast cancer

Study Identifies Why Some Breast Cancers Resist Enhertu Treatment

January 30th 2026

breast cancer

Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows

January 29th 2026

Trending on CURE

Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows

Key GI Cancer Advances from the 2026 ASCO Symposium

Ibrance Adds 15 Months of Progression-Free Survival in HR+, HER2+ Breast Cancer

Risk Assessment Remains Vital for Patients Even After Cancer Diagnosis

Study Identifies Why Some Breast Cancers Resist Enhertu Treatment